SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2013-05-16** | Period of Report: **2013-05-14** SEC Accession No. 0001225208-13-012556

(HTML Version on secdatabase.com)

ISSUER

Edwards Lifesciences Corp

CIK:1099800| IRS No.: 364316614 | State of Incorp.:DE | Fiscal Year End: 1231 SIC: 3842 Orthopedic, prosthetic & surgical appliances & supplies

Mailing Address ONE EDWARDS WAY IRVINE CA 92614

Business Address ONE EDWARDS WAY IRVINE CA 92614 9492502500

REPORTING OWNER

WANG HUIMIN

CIK:1204553

Type: 4 | Act: 34 | File No.: 001-15525 | Film No.: 13852810

Mailing Address C/O EDWARDS LIFESCIENCES ONE EDWARDS WAY IRVINE CA 92614

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Expires:	02/28/2011								
Estimated average be	urden								
hours per response	0.5								

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of R WANG HUIMIN	eporting Person 2	-	2. Issuer Name and Ticker or Trading Symbol Edwards Lifesciences Corp [EW]	Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
()		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/14/2013	Officer (give title Other (specify below) below) CVP, Japan & Intercontinental				
ONE EDWARDS WAY	7							
			4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing (Check applicable line) XForm Filed by One Reporting Person Form Filed by More than One Reporting Person				
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	(Month/ Date, if any Code		ction	of (D) (Instr. 3, 4 a	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
	Year)	Code	v	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(c.g., pats, sails, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)			3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/ Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Employee Stock Option (Right to Acquire)	\$71.57	05/14/2013		A		27,900		05/14/2014 (1)	05/13/2020	Common Stock	27,900	\$ 0	27,900 ⁽²⁾	D	
Performance Rights	(<u>3</u>)	05/14/2013		<u>A</u>		3,775 ^(<u>3</u>)		(<u>3</u>)	03/31/2016	Common Stock	3,775 ^(<u>3</u>)	\$ 0	3,775 ^(<u>3</u>)	D	

Explanation of Responses:

- 1. This option was granted on May 14, 2013 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and becomes exercisable commencing one year after the grant date in four equal annual installments.
- 2. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.
- 3. Reflects the target number of shares (the Target Award) covered by unvested Restricted Stock Units granted on May 14, 2013. The number of shares issuable at vesting will depend upon achievement of the performance goals and will range from zero percent (0%) of the Target Award to one hundred seventy five percent (175%) of the Target Award.

Signatures

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.